A myelopoiesis gene signature during remission in anti-neutrophil cytoplasm antibody-associated vasculitis does not predict relapses but seems to reflect ongoing prednisolone therapy.

摘要: A myelopoiesis gene signature in circulating leucocytes, exemplified by increased myeloperoxidase (MPO) and proteinase 3 (PR3) mRNA levels, has been reported patients with active anti-neutrophil cytoplasm antibody-associated vasculitis (AAV), to a lesser extent during remission. We hypothesized that this could predict disease relapse. levels of PR3, MPO, selected transcription factors [CCAAT/enhancer binding protein α (CEBP-α), CCAAT/enhancer β (CEBP-β), SPI1/PU.1-related factor (SPIB), spleen focus forming virus proviral integration oncogene, PU.1 homologue (SPI1)] microRNAs (miRNAs) from patient control peripheral blood mononuclear cells (PBMC) polymorphonuclear (PMN) were analysed associated clinical data. Patients stable remission had higher for PR3 (PBMC, PMN) MPO (PBMC). SPIB correlated positively controls but negatively PBMC. Statistically significant correlations existed between several miRNAs controls, not patients. PR3/MPO previous or future relapses, steroid treatment. Prednisolone doses linked miR-155-5p, miR-339-5p miR-221, miR-361 miR-505 (PMN). PBMC time since last flare, leucocyte count estimated glomerular filtration rate. Our results show elevated AAV do The origin seems multi-factorial, an important explainable prednisolone action. Gene signatures undergoing treatment should therefore be interpreted accordingly.